Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement

Project description

Biomarker-driven approaches for precision medicine in oncology

Advancing precision medicine in oncology improves patient outcomes and personalises cancer care, but limited access to validated prognostic and predictive biomarkers hinders progress. The EU-funded BRECISE project aims to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment in precision medicine. This Public-Private Partnership seeks to create a collaborative ecosystem for clinically validating Next-Generation Sequencing (NGS)-based, multi-modality artificial intelligence (AI) oncology biomarkers. The results will enable precise risk assessments and informed treatment choices, leading to more personalised care. These validated biomarker technologies will support researchers in developing safer, more effective treatments, boosting the competitiveness of European health industries and improving patient outcomes.

Objective

BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care.
BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care.

The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects. The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2024-07-single-stage

See all projects funded under this call

Coordinator

SOUTH EAST TECHNOLOGICAL UNIVERSITY
Net EU contribution
€ 813 889,81
Address
CORK ROAD CAMPUS WATERFORD
X91 K0EK Waterford
Ireland
Region
Ireland Southern South-East
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 813 889,81

Participants (25)

Partners (4)